Hoshino M
Saiseikai Yokohama City South Hospital.
Arerugi. 1994 Jun;43(6):689-95.
It is clear that bronchial asthma is caused by chronic airway inflammation. However, no standard treatment has been developed since opinions regarding the use of anti-allergic agents vary from country to country. I studied the effect of ketotifen, a popular anti-allergic drug, on inflammatory cells in bronchial mucosa. I obtained bronchial mucosa specimens by bronchoscopy from eight atopic asthmatics of mild to moderate severity before and after ketotifen (2 mg/day) treatment and also obtained from 5 normal healthy adults for control study. I used monoclonal antibodies for immunohistochemical staining: anti-EG2 for eosinophils, anti-NP57 for neutrophils, anti-CD3, anti-CD4 and anti-CD8 for T lymphocytes, anti-CD25 and anti-HLA-DR for activated T lymphocytes. I also stained mast cells with toluidine blue. The number of eosinophils, neutrophils, T lymphocytes and activated T lymphocytes in the bronchial mucosa of the asthmatic patients were significantly decreased after treatment with ketotifen. These results suggest that ketotifen decreases the inflammatory cells in the airway, and improves allergic inflammation in bronchial asthma.
显然，支气管哮喘是由慢性气道炎症引起的。然而，由于各国对抗过敏药物的使用意见不一，尚未开发出标准治疗方法。我研究了一种常用的抗过敏药物酮替芬对支气管黏膜炎症细胞的影响。我通过支气管镜检查从8名轻至中度严重程度的特应性哮喘患者在酮替芬（2毫克/天）治疗前后获取支气管黏膜标本，并从5名正常健康成年人获取标本用于对照研究。我使用单克隆抗体进行免疫组织化学染色：抗EG2用于嗜酸性粒细胞，抗NP57用于中性粒细胞，抗CD3、抗CD4和抗CD8用于T淋巴细胞，抗CD25和抗HLA-DR用于活化T淋巴细胞。我还用甲苯胺蓝对肥大细胞进行染色。哮喘患者支气管黏膜中的嗜酸性粒细胞、中性粒细胞、T淋巴细胞和活化T淋巴细胞数量在酮替芬治疗后显著减少。这些结果表明，酮替芬可减少气道中的炎症细胞，并改善支气管哮喘中的过敏性炎症。
